Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis and Toronto-based Sunnybrook Health Sciences Centre have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds such as neuropathic and neuroischemic diabetic foot ulcers.
Subscribe to our email newsletter
Vasculotide is a synthetic peptide-based growth factor which targets Tie2, a receptor on specialized cells of the hematopoietic and vascular systems.
Vasculotide was invented by Sunnybrook Research Institute scientists Dan Dumont and Paul Van Slyke.
Sanofi-aventis vice president of Therapeutic Strategy Unit, Fibrosis and Wound Repair Ray Jupp said the Sunnybrook Health Sciences Centre agreement fits the company’s strategy of fostering scientific exchange through external collaborations.
The Fibrosis and Wound Repair unit is one among five Therapeutic Strategy Units created as part of Sanofi-aventis’ new R&D model.
The unit is responsible for identifying health solutions through pooling internal and external expertise and bringing them to the clinic.
Sunnybrook vice president of Research Michael Julius said the company is grateful to their commercialization agent MaRS Innovation for identifying Sanofi-aventis as the ultimate partner to develop vasculotide further.
The agreement terms give Sanofi-aventis an exclusive worldwide option with predetermined upfront milestones and royalty payments with Sunnybrook for developing and commercializing vasculotide.